Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Allergan to Acquire ZELTIQ, Best-in-Class Company in Fast-Growing Body Contouring Segment, for $2.47 Billion

February 13, 2017
DUBLIN and PLEASANTON, Calif., Feb. 13, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, and ZELTIQ® Aesthetics, Inc. (NASDAQ: ZLTQ) a medical technology company focused on developing…

Esperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in Patients with Hypercholesterolemia

January 25, 2017
ANN ARBOR, Mich., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the…

ADMA Biologics to Acquire Certain Assets from Biotest Pharmaceuticals Corporation and Become a Vertically Integrated Commercial Plasma Products Company

January 23, 2017
RAMSEY, N.J., Jan. 23, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment…